Armistice Capital’s Kairos Pharma KAPA Stock Holding History

Armistice Capital’s Portfolio KAPA Stock Details KAPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,404,000	Closed	-$1.31M	–	283
2025 Q1	$1.31M	Buy	+1,404,000	New	+$1.8M	0.02%	158

Other funds holding KAPA

SFG

SevenBridge Financial Group Harrisburg, Pennsylvania $640M AUM 27.29% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

ACA

Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's KAPA Position: Q2 2025 in Review

Armistice Capital sold out of Kairos Pharma (KAPA) in Q2 2025, closing a stake of 1,404,000 shares — an estimated $1.31M sold.

Armistice Capital first reported a position in KAPA in Q1 2025 and held it in 1 quarter. The position peaked at $1.31M in Q1 2025. 10 funds tracked by Wall St. Rank hold KAPA as of Q2 2025.

Armistice Capital reported no remaining Kairos Pharma position as of Q2 2025 after selling out during the quarter.
Armistice Capital sold 1,404,000 Kairos Pharma shares in Q2 2025, an estimated $1.31M.
Armistice Capital first reported a position in Kairos Pharma in Q1 2025 and held it in 1 quarter.
Armistice Capital's Kairos Pharma position peaked at $1.31M in Q1 2025.
10 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.